Novartis deal in atopic diseases could be worth $1.7 billion for Relation
Privately-held UK biotech Relation Therapeutics has announced a multi-program, strategic collaboration with Swiss pharma giant Novartis (NOVN: VX) to discover and advance novel targets for atopic diseases.
Under the terms of the deal, Relation will receive $55 million, comprising an upfront payment, equity investment and additional R&D funding. The London-based company is also eligible to receive pre-clinical, development, regulatory, and commercial sales milestones of up to $1.7 billion, along with tiered royalties on net sales of products.
The collaboration pairs Relation’s AI-powered drug discovery platform and human data generation capabilities with Novartis’ deep expertise in immuno-dermatology to identify, validate, and advance potential first-in-class targets in atopic diseases driven by immune dysregulation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze